Science Daily: Pharmacology News

AUGUST 12, 2025

Scientists have discovered a direct cause-and-effect link between faulty mitochondria and the memory loss seen in neurodegenerative diseases. By creating a novel tool to boost mitochondrial activity in mouse models, researchers restored memory performance, suggesting mitochondria could be a powerful new target for treatments. The findings not only shed light on the early drivers of brain cell degeneration but also open possibilities for slowing or even preventing diseases like Alzheimer’s.

Engineering

Drug Target Review

AUGUST 12, 2025

In the race to accelerate drug discovery, artificial intelligence (AI) has already proven itself to be adept in areas like target identification, virtual screening and molecular generation. From predicting protein structures to designing entirely new compounds, AI is helping to redefine what is possible in early-stage research and development (R&D).

Drugs

Science Daily: Pharmacology News

AUGUST 8, 2025

Researchers at Scripps have created T7-ORACLE, a powerful new tool that speeds up evolution, allowing scientists to design and improve proteins thousands of times faster than nature. Using engineered bacteria and a modified viral replication system, this method can create new protein versions in days instead of months. In tests, it quickly produced enzymes that could survive extreme doses of antibiotics, showing how it could help develop better medicines, cancer treatments, and other breakthroug

Engineering

Broad Institute

AUGUST 8, 2025

Blood-based test provides new diagnostic approach for multiple myeloma By Tom Ulrich August 8, 2025 Breadcrumb Home Blood-based test provides new diagnostic approach for multiple myeloma Test of circulating tumor cells offers less invasive option for multiple myeloma surveillance, staging, and biological study compared to bone marrow biopsies By Nicole Oliverio, Dana-Farber Cancer Institute August 8, 2025 Credit: NCI Visuals Online Multiple myeloma cells (green) Related people Gad Getz Related p

Doctors

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Covalent Modifiers

AUGUST 8, 2025

Laura Hillebrand, Guiqun Wang, Alexander Rasch, Benedikt Masberg, Apirat Chaikuad, Thales Kronenberger, Ellen Günther, Michael Forster, Antti Poso, Michael Lämmerhofer, Stefan A. Laufer, Stefan Knapp, Matthias Gehringer RSC Med. Chem., 2025 [link] While cysteine targeting in kinases is well established and widely used, covalent interactions with other amino acids remain much less explored.

Crown Bioscience

AUGUST 5, 2025

The Promise of Organoids in Modern Medicine The conversation with Dr. Price underscores organoids' potential as accurate models of human tissue. Organoids are cultured cell structures that mimic the complexities of human organs, allowing researchers to study them under conditions that closely replicate real biological environments. The shift from traditional 2D cell lines to 3D organoids provides a more relevant context for understanding diseases and testing treatments.

Drug Development

Broad Institute

AUGUST 5, 2025

CDoT landing page By Rose Circeo August 5, 2025 Breadcrumb Home CDoT landing page Featured description text here Broad scientists are continually making new biological discoveries that have the potential to create new and transformative medicines. In some cases, industry will recognize a novel insight emerging from the Broad and successfully launch a drug discovery project; more often, biological discoveries require additional work to move them to a point where industry is willing and able to ‘t

Small Molecule

Chemical Biology and Drug Design

AUGUST 6, 2025

Repurposing of effectively lipophilic fluoroquinolones and pyridoquinoxalines (PQs) conjugated to gold nanoparticles pharmacology for synergistic and proapoptogenic cytotoxicity drug design and targeted delivery. ABSTRACT In a world where cancer continues to be a major health problem, the urgency continues to find new effective treatments. This work involved the synthesis of more than 10 anticancer fluoroquinolones (FQs) and pyridoquinoxaline (PQ) derivatives originating from FQs and studied the

DNA

Drug Target Review

AUGUST 12, 2025

The past few years have seen a boom in the market for protein- and peptide-based drugs, with the global market for peptide-based drugs expected to reach approximately $80 billion by 2032. 1 The primary reason is that peptide-based drugs can be highly effective, 2 leading to fewer off-target interactions and excellent biocompatibility. However, some of the major issues with these potentially game-changing therapeutic agents include their short lifespan within the body (they are prone to hydrolysi

Drug Development

Crown Bioscience

AUGUST 5, 2025

The Promise of Organoids in Modern Medicine The conversation with Dr. Price underscores organoids' potential as accurate models of human tissue. Organoids are cultured cell structures that mimic the complexities of human organs, allowing researchers to study them under conditions that closely replicate real biological environments. The shift from traditional 2D cell lines to 3D organoids provides a more relevant context for understanding diseases and testing treatments.

Drug Development

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Broad Institute

AUGUST 6, 2025

Scientists develop technology that brings new precision to genome editing By Tom Ulrich August 6, 2025 Breadcrumb Home Scientists develop technology that brings new precision to genome editing Fast-acting, cell-permeable protein system that controls CRISPR-Cas9 could reduce off-target effects and advance gene therapy By Danielle Doughty, MIT Department of Chemistry August 6, 2025 Credit: Vera AO et al.

DNA

Drug Patent Watch

AUGUST 8, 2025

"The Prescription for Innovation: How AI and Machine Learning Are Revolutionizing Pharmaceutical IP Strategy As the pharmaceutical industry grapples with the complexities of patent law, a new player is emerging: artificial intelligence. In a groundbreaking shift, AI and machine learning are being harnessed to forge the next frontier of pharmaceutical IP strategy.

Pharmaceuticals

Drug Target Review

AUGUST 6, 2025

ATP citrate lyase (ACLY) is a central enzyme in metabolism, best known for its role in cholesterol and fatty acid synthesis. A validated target in cardiovascular disease, new research from Esperion Therapeutics suggests that ACLY could also play a role in liver disease – specifically, primary sclerosing cholangitis (PSC). PSC is a rare, chronic cholestatic liver disorder with no approved treatments.

Therapies

Twist Bioscience

AUGUST 11, 2025

A Simple Guide to Phosphoramidite Chemistry and How it Fits in Twist Bioscience's Commercial Engine Anonymous (not verified) Mon, 08/11/2025 - 10:40 Science Phosphoramidite chemistry is the gold standard method for DNA synthesis that has been used in the industry for almost 35 years. Since its discovery, its simplicity and high efficiency have allowed large volumes of oligonucleotide sequences to be synthesized up to 200 base pairs in length.

Engineering

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Science Daily: Pharmacology News

AUGUST 9, 2025

Researchers at the Salk Institute have used CRISPR to uncover hidden microproteins that control fat cell growth and lipid storage, identifying one confirmed target, Adipocyte-smORF-1183. This breakthrough could lead to more effective obesity treatments, surpassing the limitations of current drugs like GLP-1.

Treatment

Drugs.com

AUGUST 11, 2025

MONDAY, Aug. 11, 2025 — A newly approved implant appears to slow vision loss from a rare and previously untreatable eye disease, researchers report. The eye implant, called ENCELTO, gradually releases proteins that protect light-sensing nerve.

Disease

BioPharma Drive: Drug Pricing

AUGUST 7, 2025

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts anticipated, leading to a selloff in shares that erased about $100 billion in market value.

Trials

Drug Target Review

AUGUST 8, 2025

Market outlook: A new wave of biologics The biologics market is evolving rapidly. While monoclonal antibodies and antibody-drug conjugates continue to drive therapeutic pipelines, bispecific T-cell engagers (TCEs) are gaining momentum as a versatile and scalable class of immunotherapies. These molecules are designed to harness the immune system’s cytotoxic potential by simultaneously binding a tumour antigen and the CD3 receptor on T-cells, effectively bringing immune effectors into direct conta

Engineering

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Crown Bioscience

AUGUST 7, 2025

Acute myeloid leukemia (AML) remains one of the most aggressive hematological malignancies, characterized by the rapid proliferation of immature myeloid cells in the bone marrow and blood. Despite advances in chemotherapy and hematopoietic stem cell transplantation, AML continues to pose significant clinical challenges due to its high relapse rate, clonal heterogeneity, and resistance to standard therapies.

Drug Development

Science Daily: Pharmacology News

AUGUST 8, 2025

High-fat diets and obesity reshape astrocytes—star-shaped brain cells in the striatum that help regulate pleasure from eating. French researchers discovered that tweaking these cells in mice not only impacts metabolism but can also restore cognitive abilities impaired by obesity, such as relearning tasks. This breakthrough highlights astrocytes as powerful players in brain function and energy control, opening fresh possibilities for targeted obesity treatments.

Regulations

Drugs.com

AUGUST 7, 2025

THURSDAY, Aug. 7, 2025 -- The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis (RA).The SetPoint System is indicated.

FDA Approval

BioPharma Drive: Drug Pricing

AUGUST 7, 2025

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new partner.

Drugs

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Chemical Biology and Drug Design

AUGUST 11, 2025

Novel glyco-triazole-metronidazole compounds obtained via a click chemistry reaction—used as antifungal and antifungal biofilm agents. Subsequent antifungal tests showed good results for a number of compounds which are believed to essentially function as a bioactive “Trojan horse.” ABSTRACT Carbohydrates are well known to be one of the most abundant and structurally diverse natural organic compounds, and they are of great importance as an energy source and as structural components of cell walls

Treatment

Quanticate

AUGUST 7, 2025

Discover how patient reported outcomes enhance trial design, boost engagement and deliver real-world insights with ePRO, PROMIS measures & real-time dashboards.

Clinical Trials

Science Daily: Pharmacology News

AUGUST 9, 2025

Scientists have uncovered a way to promote weight loss and improve blood sugar control without the unpleasant side effects of current GLP-1 drugs. By shifting focus from neurons to brain support cells that produce appetite-suppressing molecules, they developed a modified compound, TDN, that worked in animal tests without causing nausea or vomiting.

Animal Testing

Drugs.com

AUGUST 6, 2025

WEDNESDAY, Aug. 6, 2025 -- The U.S. Food and Drug Administration has approved Vizz 1.44 percent (aceclidine ophthalmic solution) for the treatment of presbyopia in adults. Vizz is the first and only aceclidine-based eye drop to improve near vision.

FDA Approval

Drug Patent Watch

AUGUST 7, 2025

"The Enablement Ruling That Will Shake the Biologics Industry: What Amgen v. Sanofi Means for Your Patent Strategy As the biologics landscape continues to evolve, a recent Supreme Court ruling has sent shockwaves through the industry. In Amgen v. Sanofi, the court's enablement decision has significant implications for biologic patent holders and those seeking to challenge existing patents.

Covalent Modifiers

AUGUST 9, 2025

Qian Wen Tan, Subramanyam Vankadara, Jia Yi Fong, Yi Yang See, Nithya Baburajendran, Pearly Shuyi Ng, Weijun Xu, Yee Khoon Yeo, Weiling Wang, Choon Heng Low, Li Hong Tan, Eileen Gui Ju Tay, Yun Xuan Wong, Chuhui Huang, Sandra Sim, Shi Hua Ang, Hannah Hui Min Toh, Juliana Mohammad, Gang Wang, Boping Liu, Shu Ting Tan, Perlyn Zekui Kwek, Monique Danielle Dawson, Qin Yao Oh, Xiaoying Koh, Joma Joy, May Ann Lee, Walter Stunkel, Vishal Pendharkar, Hannes Hentze, Siew Pheng Lim, Kantharaj Ethirajulu,

Pharmacokinetics

Quanticate

AUGUST 6, 2025

Artificial intelligence (AI) and machine learning (ML) are playing an increasingly central role in clinical trials. By automating routine tasks and enabling real-time analysis, these technologies are helping data management teams keep pace with growing data volumes and regulatory expectations.

Clinical Trials

Science Daily: Pharmacology News

AUGUST 11, 2025

Scientists have discovered a parasite that can sneak into your skin without you feeling a thing. The worm, Schistosoma mansoni, has evolved a way to switch off the body’s pain and itch signals, letting it invade undetected. By blocking certain nerve pathways, it avoids triggering the immune system’s alarms. This stealth tactic not only helps the worm survive, but could inspire new kinds of pain treatments and even preventative creams to protect people from infection.

Treatment

Drugs.com

AUGUST 7, 2025

THURSDAY, Aug. 7, 2025 — Researchers have debunked long-standing concerns that Tamiflu can cause neurological and psychiatric problems when given to influenza-stricken children.For decades, doctors have debated whether the antiviral drug o.

Doctors

Codon

AUGUST 7, 2025

Sunlight represents a seemingly endless source of largely untapped energy. Just how endless is it?